(2-chlorophenyl) carbonochloridate

反応条件: temp:0.00; pressure:0.00; stir:

反応条件: temp:0.00; pressure:0.00; stir:

反応条件: temp:0.00; pressure:0.00; stir:

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: 2-(chloro)phenyl chloroformate (5.00 g, 26.2 mmol) was added to a solution of tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (4.50 g, 20.2 mmol) according to general procedure 1. Yield=4.56 g, 82%. m/z MH+=278.13. HPLC rt=9.3 min. HPLC rt=9.3 min.

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: 2-(chloro)phenyl chloroformate (5.00 g, 26.2 mmol) was added to a solution of tert-butyl 4-(prop-2-ynyl)piperidine-1-carboxylate (4.50 g, 20.2 mmol) according to general procedure 1. Yield=4.56 g, 82%. m/z MH+=278.13. HPLC rt=9.3 min. HPLC rt=9.3 min.

反応条件: temp:0.00; pressure:0.00; stir:

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: The title compound was prepared from [4-(3-amino-phenyl)-8-trifluoromethyl-quinolin-3-yl]-phenyl-methanone and 2-chlorophenyl chloroformate according to the procedure of Example 65. MS (ES) m/z 546.9.

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: Example 22 was prepared according to procedures described in Example 2, Step A and Step C, substituting tert-butyl 3-((1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)methyl)azetidine-1-carboxylate for tert-butyl 4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate in Step A and 2-chlorophenyl chloroformate for 1,1,1-trifluoropropan-2-yl chloroformate in Step C. 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J=8.25 Hz, 2 H), 7.62 (d, J=8.25 Hz, 2 H), 7.43 (dd, J=7.97, 1.37 Hz, 1 H), 7.32 (d, J=7.70 Hz, 1 H), 7.16-7.31 (m, 3 H), 6.28 (d, J=2.20 Hz, 1 H), 6.25 (dd, J=7.70, 2.75 Hz, 1 H), 4.41 (app brs, 1 H), 4.31 (app brs, 1 H), 4.23 (d, J=6.05 Hz, 2 H), 4.20 (app brs, 1 H), 4.04 (app brs, 1 H) 3.15-3.26 (m, 1 H), 3.11 (s, 3 H). MS (ESI) 489 (M+H). Example 22 was prepared

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: Example 19 was prepared according to procedures described in Example 2, Step A and Step C, substituting tert-butyl 3-((1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)methyl)pyrrolidine-1-carboxylate for tert-butyl 4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate in Step A and 2-chlorophenyl chloroformate for 1,1,1-trifluoropropan-2-yl chloroformate in Step C. 1H NMR (500 MHz, CDCl3) δ 8.08 (d, J=8.80 Hz, 2 H), 7.61 (d, J=8.80 Hz, 2 H), 7.43 (d, J=8.25 Hz, 1 H), 7.23-7.31 (m, 3 H), 7.14-7.19 (m, 1 H), 6.10-6.21 (m, 2 H), 3.38-4.14 (m, 6 H), 3.10 (s, 3 H), 2.77-2.93 (m, 1 H), 2.15-2.32 (m, 1 H), 1.83-2.00 (m, 1 H). MS (ESI) 503 (M+H). Example 19 was prepared

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: Example 22 was prepared according to procedures described in Example 2, Step A and Step C, substituting tert-butyl 3-((1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)methyl)azetidine-1-carboxylate for tert-butyl 4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate in Step A and 2-chlorophenyl chloroformate for 1,1,1-trifluoropropan-2-yl chloroformate in Step C. 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J=8.25 Hz, 2H), 7.62 (d, J=8.25 Hz, 2H), 7.43 (dd, J=7.97, 1.37 Hz, 1H), 7.32 (d, J=7.70 Hz, 1H), 7.16-7.31 (m, 3H), 6.28 (d, J=2.20 Hz, 1H), 6.25 (dd, J=7.70, 2.75 Hz, 1H), 4.41 (app brs, 1H), 4.31 (app brs, 1H), 4.23 (d, J=6.05 Hz, 2H), 4.20 (app brs, 1H), 4.04 (app brs, 1H) 3.15-3.26 (m, 1H), 3.11 (s, 3H). MS (ESI) 489 (M+H). Example 22 was prepared

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: Example 19 was prepared according to procedures described in Example 2, Step A and Step C, substituting tert-butyl 3-((1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)methyl)pyrrolidine-1-carboxylate for tert-butyl 4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate in Step A and 2-chlorophenyl chloroformate for 1,1,1-trifluoropropan-2-yl chloroformate in Step C. 1H NMR (500 MHz, CDCl3) δ 8.08 (d, J=8.80 Hz, 2H), 7.61 (d, J=8.80 Hz, 2H), 7.43 (d, J=8.25 Hz, 1H), 7.23-7.31 (m, 3H), 7.14-7.19 (m, 1H), 6.10-6.21 (m, 2H), 3.38-4.14 (m, 6H), 3.10 (s, 3H), 2.77-2.93 (m, 1 H), 2.15-2.32 (m, 1H), 1.83-2.00 (m, 1H). MS (ESI) 503 (M+H). Example 19 was prepared

反応条件: temp:0.00; pressure:0.00; stir:; See reaction.notes.procedure_details.

実験手順: Example 22 was prepared according to procedures described in Example 2, Step A and Step C, substituting tert-butyl 3-((1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)methyl)azetidine-1-carboxylate for tert-butyl 4-(1-(4-(methylsulfonyl)phenyl)-2-oxo-1,2-dihydropyridin-4-yloxy)piperidine-1-carboxylate in Step A and 2-chlorophenyl chloroformate for 1,1,1-trifluoropropan-2-yl chloroformate in Step C. 1H NMR (500 MHz, CDCl3) δ 8.09 (d, J=8.25 Hz, 2 H), 7.62 (d, J=8.25 Hz, 2 H), 7.43 (dd, J=7.97, 1.37 Hz, 1H), 7.32 (d, J=7.70 Hz, 1 H), 7.16-7.31 (m, 3H), 6.28 (d, J=2.20 Hz, 1 H), 6.25 (dd, J=7.70, 2.75 Hz, 1 H), 4.41 (app brs, 1 H), 4.31 (app brs, 1 H), 4.23 (d, J=6.05 Hz, 2 H), 4.20 (app brs, 1 H), 4.04 (app brs, 1 H) 3.15-3.26 (m, 1 H), 3.11 (s, 3 H). MS (ESI) 489 (M+H). Example 22 was prepared